FivepHusion
Melbourne, Australia· Est.
Australianbiotech developing a pH‑optimized 5‑FU/leucovorin combo to enhance safety and efficacy across solid and paediatric brain cancers.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
Australianbiotech developing a pH‑optimized 5‑FU/leucovorin combo to enhance safety and efficacy across solid and paediatric brain cancers.
Oncology
Technology Platform
All‑in‑one pH‑optimized formulation of 5‑FU and leucovorin for systemic delivery, plus the ResectAssist™ platform for localized drug deposition into solid tumours.
Opportunities
Successful Phase III data could enable market entry as a premium 5‑FU alternative and open licensing or partnership deals for the ResectAssist™ platform.
Risk Factors
Clinical development delays, regulatory hurdles, and the need for substantial financing to advance to commercial stage pose significant risks.
Competitive Landscape
Deflexifol™ differentiates from generic 5‑FU by improved tolerability and efficacy, while ResectAssist™ offers a novel localized delivery approach not widely available from competitors.